Jacobs Levy Equity Management Inc. Increases Stock Holdings in USANA Health Sciences, Inc. (NYSE:USNA)

Jacobs Levy Equity Management Inc. increased its holdings in USANA Health Sciences, Inc. (NYSE:USNA) by 16.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 128,976 shares of the company’s stock after purchasing an additional 18,490 shares during the period. Jacobs Levy Equity Management Inc.’s holdings in USANA Health Sciences were worth $4,629,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in USNA. Dimensional Fund Advisors LP grew its position in shares of USANA Health Sciences by 7.7% in the fourth quarter. Dimensional Fund Advisors LP now owns 773,228 shares of the company’s stock valued at $27,751,000 after purchasing an additional 55,059 shares during the period. Pacer Advisors Inc. grew its position in shares of USANA Health Sciences by 8.8% in the fourth quarter. Pacer Advisors Inc. now owns 592,001 shares of the company’s stock valued at $21,247,000 after purchasing an additional 47,745 shares during the period. Pzena Investment Management LLC grew its position in shares of USANA Health Sciences by 3.6% in the fourth quarter. Pzena Investment Management LLC now owns 1,087,076 shares of the company’s stock valued at $39,015,000 after purchasing an additional 37,466 shares during the period. Jane Street Group LLC boosted its holdings in USANA Health Sciences by 330.0% in the fourth quarter. Jane Street Group LLC now owns 39,979 shares of the company’s stock valued at $1,435,000 after acquiring an additional 30,681 shares during the last quarter. Finally, Norges Bank acquired a new position in USANA Health Sciences in the fourth quarter valued at $953,000. Hedge funds and other institutional investors own 54.25% of the company’s stock.

Insiders Place Their Bets

In other USANA Health Sciences news, CFO G Doug Iiekking sold 4,548 shares of the business’s stock in a transaction on Friday, May 9th. The shares were sold at an average price of $29.61, for a total value of $134,666.28. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider David Mulham Mulham sold 3,234 shares of the business’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the completion of the transaction, the insider now owns 12,775 shares in the company, valued at $421,319.50. This represents a 20.20% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 21,142 shares of company stock worth $655,050 in the last 90 days. 0.63% of the stock is owned by company insiders.

USANA Health Sciences Trading Down 1.8%

Shares of USANA Health Sciences stock opened at $29.20 on Thursday. USANA Health Sciences, Inc. has a twelve month low of $23.10 and a twelve month high of $49.78. The stock has a market capitalization of $543.79 million, a P/E ratio of 10.32, a PEG ratio of 0.93 and a beta of 0.60. The business’s fifty day moving average price is $27.20 and its 200 day moving average price is $32.56.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share for the quarter, topping the consensus estimate of $0.70 by $0.03. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $249.54 million during the quarter, compared to the consensus estimate of $243.08 million. During the same quarter in the prior year, the business earned $0.86 earnings per share. As a group, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the company. DA Davidson reduced their target price on USANA Health Sciences from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Thursday, February 27th. Sidoti cut USANA Health Sciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 18th. Finally, StockNews.com cut USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, February 14th.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.